While Mohs surgery has proven to be extremely effective at treating non-melanoma skin cancers like basal cell carcinoma and squamous cell carcinoma, there are huge drawbacks to the procedure from the perspective of the patient. Depending on the operation, Mohs surgery can leave behind large, nasty scarring that requires reconstructive surgery by a plastic surgeon.
Tell Your Patients About The SRT-100™
Sensus Healthcare is proud to offer another solution for the treatment of non-melanoma skin cancers: The SRT-100™. This revolutionary machine is the best option for non-invasive basal cell carcinoma and squamous cell carcinoma treatment.
Non-Invasive Basal Cell Carcinoma Treatment
Using a precise, calibrated dose of Superficial Radio Therapy, the SRT-100™ effectively destroys skin cancer cells, as well as the non-malignant tumor cells that cause the growth of keloids.
The procedure can be performed right in your office. The radiation only goes skin deep, so there is no cutting, bleeding, or stitching. Because the procedure is virtually painless, anesthesia is not needed. Patients heal quickly after treatment and have no downtime or restrictions on their current way of life.
Designed for Effective Treatment
The SRT-100™ has many features aimed at increasing the effectiveness of SRT treatment:
1. A broad range of motion
The scissor arm has a wide vertical and horizontal range to accommodate patients whether they lie down or sit.
2. Precise dosage
The high-frequency inverter technology ensures stability in kV-mA energy levels.
3. Auto warmup
The automatic warm-up function allows for even quicker treatment time. The machine is ready to go in under six minutes.
4. Automatic aluminum filter magazine
After kV-mA levels have been selected, the machine automatically changes the aluminum filter, removing the need for storage, manual procedure, and the possibility of accidental over- or under-dosage.
Are you interested in learning more about the SRT-100™ as a Mohs surgery alternative for your practice? Contact Sensus Healthcare today.